Kenya Launches Advanced Nuclear Cancer Therapy, Pioneering New Hope for Patients
In a landmark move for East African healthcare, Kenya has introduced a sophisticated form of nuclear therapy to combat cancer, offering a powerful new weapon in a fight that affects thousands. This advanced treatment, known as theranostics, represents a significant leap forward in oncology, providing a more precise and less invasive option for patients.
A Pinpoint Approach to Destroying Tumors
So, how does this new therapy work? Unlike conventional treatments that can affect the entire body, theranostics uses a two-pronged approach. A radioactive drug is injected into the patient, which travels through the bloodstream and binds specifically to cancer cells. Once attached, the radiation works from the inside out to destroy the tumor while largely sparing surrounding healthy tissue.
Medical specialists champion this method as a safer and often more effective alternative to traditional chemotherapy and radiotherapy, which are notorious for their debilitating side effects.
KUTRRH Leads the Regional Charge
The Kenyatta University Teaching, Referral and Research Hospital (KUTRRH) is the epicenter of this medical breakthrough, becoming the first facility in Kenya and the wider East African region to offer nuclear medicine for cancer. The launch was accompanied by specialized training for medical professionals, featuring both local and international nuclear medicine experts.
Dr. Harish Nagaraj, Consultant and Head of Nuclear Medicine at KUTRRH’s Molecular Imaging Centre, explained that the therapy is particularly transformative for cancers like prostate and breast cancer that have proven resistant to standard treatments. “This is a targeted strike against the disease,” Dr. Nagaraj stated.
Navigating Cost and Accessibility
Despite its promise, the treatment comes with a substantial price tag. Each cycle costs approximately 1.3 million Kenyan shillings, and a patient typically needs four to six cycles. Dr. Nagaraj emphasized that while the cost is high, the precision and effectiveness justify the investment. He also highlighted a critical hurdle: “Nuclear therapy requires significant funding, which is why support from the government and donors is crucial since it’s not yet covered by the Social Health Authority.”
There is, however, a concerted effort to change this. Dr. Andrew Toro, a Director in the Department of Medical Services, confirmed that discussions are actively underway to include the therapy under national insurance coverage, which would dramatically improve patient access.
International Experts Validate Safety and Efficacy
Visiting specialists from the International Atomic Energy Agency (IAEA) have given the treatment their full endorsement. Dr. Janke Kleynhans and Professor Jan Zeevaart were on hand to allay any public concerns, stressing the procedure’s safety profile.
“Unlike conventional oncology drugs that affect the entire body, this treatment directly targets the tumor and is safely eliminated afterward,” Dr. Kleynhans explained. “It’s among the safest and most effective cancer therapies available today.”
Shifting Public Perception on Nuclear Science
A parallel challenge involves changing the public narrative around nuclear technology. Dr. Frank Sawanga, a Deputy Director in the State Department for Science, Research and Innovation, urged Kenyans to look beyond misconceptions that link nuclear science solely to radiation and weaponry.
“We need stronger science diplomacy to help the public understand the profound benefits of nuclear applications in healthcare,” Dr. Sawanga remarked, pointing to theranostics as a prime example of nuclear technology saving lives.
Echoing this forward-looking vision, KUTRRH Chief Executive Dr. Zainab Gura reaffirmed the hospital’s commitment to establishing itself as a regional leader in nuclear medicine, signaling a new era of advanced, specialized care for Kenyans and their neighbors.
Source: By Muoki Charles / Kenya News Agency